Department of Critical Care Medicine, Jiangdu People's Hospital of Yangzhou, Jiangdu People's Hospital Affiliated to Medical College of Yangzhou University, Yangzhou, Jiangsu 225200, China.
Department of Critical Care Medicine, Northern Jiangsu People's Hospital, Yangzhou, Jiangsu Province, China.
Heart Lung. 2022 May-Jun;53:51-60. doi: 10.1016/j.hrtlng.2022.01.019. Epub 2022 Feb 1.
Convalescent plasma treatment for severe and critically ill Corona Virus Disease 2019 (COVID-19) patients remains controversial.
To evaluate the clinical improvement and mortality risk of convalescent plasma treatment in patients with severe and critically ill COVID-19 patients.
A literature search was conducted in the electronic databases for the randomized controlled studies about convalescent plasma therapy in severe and critically ill COVID-19 patients. Two reviewers independently extracted relevant data. The primary outcomes were clinical improvement and mortality risk of severe and critically ill COVID-19 patients that were therapied by convalescent plasma.
A total of 14 randomized controlled trials with 4543 patients were included in this meta-analysis. Compared to control, no significant difference was observed for either clinical improvement (6 studies, RR 1.07, 95% CI 0.97 to 1.17, p = 0.16, moderate certainty) or mortality risk (14 studies, RR 0.94, 95% CI 0.85 to 1.03, p= 0.18, low certainty) in patients of convalescent plasma therapy group.
Convalescent plasma did not increase the clinical improvement or reduce the mortality risk in the severe and critically ill COVID-19 patients.
恢复期血浆治疗严重和危重新冠病毒病 2019（COVID-19）患者仍然存在争议。
评估恢复期血浆治疗严重和危重新冠病毒病 2019（COVID-19）患者的临床改善和死亡风险。
在电子数据库中对严重和危重新冠病毒病 2019 患者恢复期血浆治疗的随机对照研究进行文献检索。两位评审员独立提取相关数据。主要结局是接受恢复期血浆治疗的严重和危重新冠病毒病 2019 患者的临床改善和死亡风险。
这项荟萃分析共纳入了 14 项随机对照试验，共 4543 名患者。与对照组相比，接受恢复期血浆治疗的患者在临床改善（6 项研究，RR 1.07，95%CI 0.97 至 1.17，p=0.16，中等确定性）或死亡率风险（14 项研究，RR 0.94，95%CI 0.85 至 1.03，p=0.18，低确定性）方面均无显著差异。
恢复期血浆并未增加严重和危重新冠病毒病 2019 患者的临床改善或降低死亡率风险。
